Wei Yun-fei, Gu Xiao-jian, Zhu Qing-yi
Zhonghua Nan Ke Xue. 2016 May;22(5):455-61.
The diagnosis and treatment of prostate cancer are being improved due to the popularized screening of prostate specific antigen. Advanced prostate cancer, in spite of its response to androgen deprivation therapy, may finally develop into castration-resistant prostate cancer (CRPC) and shorten the overall survival of the patients. Many efforts have been made by worldwide researchers for new approaches to the management of CRPC, including new hormonal therapy, cytotoxic chemotherapy, immunotherapy, and bone metastasis-targeted therapy. This paper reviews the emerging agents undergoing clinical evaluation and drugs that have received approval for the treatment of CRPC in order to provide doctors and patients with more treatment options for CRPC and improve the overall survival rate and quality of life of the patients.
由于前列腺特异性抗原筛查的普及，前列腺癌的诊断和治疗正在得到改善。晚期前列腺癌尽管对雄激素剥夺疗法有反应，但最终可能发展为去势抵抗性前列腺癌（CRPC），并缩短患者的总生存期。世界各地的研究人员为CRPC的管理新方法做出了许多努力，包括新的激素疗法、细胞毒性化疗、免疫疗法和骨转移靶向疗法。本文综述了正在进行临床评估的新兴药物以及已获批用于治疗CRPC的药物，以便为医生和患者提供更多CRPC的治疗选择，并提高患者的总生存率和生活质量。
